Faheem Hasnain sold $181k of KURA
director at Kura Oncology, Inc.. 22,682 shares at an average of $8.00, traded Mar 21, 2025, filed Mar 24, 2025.
Score components
- +15RoleDirector
- +12Trade size$181k at market
- +10Share of holdings soldSold 49% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-043903, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 21, 2025 | MOption exercise Common Stock10b5-1 | +22,682 | $6.32 | $143k | 46,665 | Mar 24, 2025 |
| Mar 21, 2025 | SOpen-market sale Common Stock10b5-1 | -22,682 | $8.00 | $181k | 23,983 | Mar 24, 2025 |
Related signals
Other insiders at Kura Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $89k 8,442 shares | -4% | |
| 37Weak | Kura Oncology, Inc. | Thomas James Doyle SVP, Finance & Accounting | $48k 4,607 shares | -3% | |
| 25Weak | Kura Oncology, Inc. | Kathleen Ford Chief Operating Officer | $112k 10,574 shares | -7% | |
| 30Weak | Kura Oncology, Inc. | Brian T. Powl Chief Commercial Officer | $345k 32,450 shares | -19% | |
| 32Weak | Kura Oncology, Inc. | Mollie Leoni Chief Medical Officer | $440k 41,250 shares | -23% | |
| 37Weak | Kura Oncology, Inc. | Francis Burrows Chief Scientific Officer | $225k 20,726 shares | -33% | |
| 31Weak | Kura Oncology, Inc. | Francis Burrows Chief Scientific Officer | $232k 23,726 shares | -41% | |
| 8Weak | Kura Oncology, Inc. | Faheem Hasnain director | $110k 10,000 shares | -29% | |
| 20Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $98k 8,804 shares | -4% | |
| 37Weak | Kura Oncology, Inc. | Thomas James Doyle SVP, Finance & Accounting | $51k 4,539 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.